Xian-Hua-Cha for Relieving Hyperlipidemia With Obesity

Chang Gung Medical Foundation

Status and phase: Enrolling; Phase 3

Conditions: Hyperlipidemias; Obesity; Body Fat Disorder

Treatments: Drug: Xian-Hua-Cha

Study type: Interventional

Funder types: Other

Identifiers

NCT05632068

KMRPC5M001

Details and patient eligibility

About

In the past decades, lipid and body fat disorders become a serious global healthcare issue, especially among the obese population. The aim of this study is to include 100 selected patients with BMI higher than 27 and hyperlipidemia, and a crossover design is used to explore the efficacy of "Xian-Hua-Cha (XHC)" on relieving hyperlipidemia among obese patient. For this purpose, the changes of patients' body weight, body fat and the metabolic parameter including blood sugar, cholesterol, triglyceride are analyzed in the end of this study.

Full description

Recently, there are more and more studies show the natural herbal products can improve obesity and related metabolic disorders through changing the body composition and even body weight, but most of the studies are still at the phase of animal studies.

In the ancient Chinese medical book Danxi's mastery of medicine mentioned "Overweight people often have phlegm." From the past observational study, obesity is related phlegm, and the recent concept shows that obesity is a chronic inflammation disease. Therefore, we combined phlegm removal herbal medicine and Chinese medicine for clearing heat and detoxifying together for obese patients with lipid disorders in clinical practice. The aim of this study is to include 100 selected patients with BMI higher than 27 and hyperlipidemia, and a crossover design is used to analyze the efficacy of "Xian-Hua-Cha (XHC)" on relieving hyperlipidemia among the obese population. For this reason, the changes of patients' body weight, body fat and the metabolic parameter including blood sugar, cholesterol, triglyceride are collected for analysis. Besides, we also record adverse effects from taking XHC to assess the safety of XHC.

Enrollment: 100 estimated patients

Sex: All

Ages: 20 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. BMI ≧ 27kg/m2
2. Total cholesterol > 200 mg/dL or LDL > 130 mg/dL or triglyceride > 150 mg/dL
3. Age ≧ 20 years and < 75 years
4. No recognition difficulties
5. Willing to sign inform consent and comply to protocol

Exclusion criteria

1. Pregnant or breast-feeding women
2. Endocrine disorders (uncontrolled hypo/hyperthyroidism, adrenal gland disorder)
3. Diagnosis of neurologic or psychiatric diseases
4. Liver or renal dysfunction (AST/ALT higher than 3 times of upper normal limits; eGFR < 60 mL/min/1.73 m2)
5. Acute stress condition (severe infection, receive major surgery in the recent 1 month)
6. Vision, or hearing impairment
7. With other clinical trial medication
8. With medication for obesity or hyperlipidemia in the recent 1 month
9. Heavy smoker, alcoholism or substance abuse
10. Severe organ dysfunction: malignancies, autoimmune diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Xian-Hua-Cha (XHC) group

Experimental group

Description:

Xian-Hua-Cha (XHC) 520 mL, twice a day will be given with diet education/monitoring program for this group for 3 months, followed by one-month wash-out period and a 3-month period with diet education/monitor program alone.

Treatment:

Drug: Xian-Hua-Cha

Control group

No Intervention group

Description:

Diet education/monitoring program (500 kcal lower than estimated total energy expenditure of each subject) will be given to each subject for 3 months first, followed by one month wash-out period and a 3-month period of Xian-Hua-Cha (XHC) 520 mL, twice a day, intervention course.